Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CA1 | P00915 | 12/20 | 0.53 |
| ▸ | CA2 | P00918 | 12/20 | 0.53 |
| ▸ | CA4 | P22748 | 12/20 | 0.53 |
| ▸ | CA6 | P23280 | 12/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29454522 | 1.00 | MEN1 (1.00) | MEN1KMT2AALOX15TDP1CA1 | |
| SCHEMBL29454627 | 1.00 | MEN1 (1.00) | MEN1KMT2AALOX15TDP1CA1 | |
| SCHEMBL1987408 | 0.84 | MEN1 (0.71) | MEN1KMT2AALOX15TDP1CA1 | |
| SCHEMBL1985243 | 0.84 | MEN1 (0.71) | MEN1KMT2AALOX15TDP1CA1 | |
| SCHEMBL1986592 | 0.84 | MEN1 (0.71) | MEN1KMT2AALOX15TDP1CA1 | |
| SCHEMBL13219145 | 0.84 | MEN1 (0.71) | MEN1KMT2AALOX15TDP1CA1 | |
| SCHEMBL1985758 | 0.80 | KMT2A (0.66) | MEN1KMT2AALOX15TDP1CA1 | |
| SCHEMBL13219151 | 0.80 | MEN1 (0.66) | MEN1KMT2AALOX15TDP1CA1 | |
| SCHEMBL1987177 | 0.80 | KMT2A (0.66) | MEN1KMT2AALOX15TDP1CA1 | |
| SCHEMBL1983834 | 0.74 | MEN1 (0.56) | MEN1KMT2AALOX15TDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048900-B2 | Use of 15-lipoxygenase inhibitors for treating obesity | GENFIT S.A. (FR) | 2011-11-01 | — | — | US | claimed |
| US-20090060905-A1 | Use of 15-Lipoxygenase Inhibitors for Treating Obesity | GENFIT (FR) | 2009-03-05 | — | — | US | claimed |
| EP-1666883-A1 | Diagnostic and monitoring methods for bone loss | F. Hoffmann-La Roche AG (CH) | 2006-06-07 | — | — | EP | claimed |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | REGENERON PHARMA (US) | 2026-04-09 | — | — | US | disclosed |
| US-12472241-B2 | Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-11845989-B2 | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-11767526-B2 | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11512309-B2 | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| US-20220089664-A1 | Treatment Of Ophthalmic Conditions With Angiopoietin-Like 7 (ANGPTL7) Inhibitors | REGENERON PHARMA (US) | 2022-03-24 | — | — | US | disclosed |
| US-20210361693-A1 | PROCESS TO INHIBIT OR ELIMINATE EOSINOPHILIC DISEASES OF THE AIRWAY AND RELATED CONDITIONS | EMPIRICO INC. | 2021-11-25 | — | — | US | disclosed |
| EP-3902567-A2 | TREATMENT OF RESPIRATORY DISORDERS WITH ARACHIDONATE15-LIPOXYGENASE (ALOX15) INHIBITORS | Regeneron Pharmaceuticals, Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20060116513-A1 | Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
| US-20060116415-A1 | Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
| WO-2006047017-A1 | NOVEL TETRACYCLIC HETEROATOM CONTAINING DERIVATIVES USEFUL AS SEX STEROID HORMONE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-04 | — | — | WO | disclosed |
| US-20060079488-A1 | Methods of treating and preventing bone loss | ALLARD JOHN D | 2006-04-13 | — | — | US | disclosed |
| WO-2006034090-A1 | NOVEL TETRACYCLIC HETEROATOM CONTAINING DERIVATIVES USEFUL AS SEX STEROID HORMONE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-30 | — | — | WO | disclosed |
| EP-1634618-A1 | Method for identifying compounds that increase bone mineral density | F. Hoffmann-La Roche AG (CH) | 2006-03-15 | — | — | EP | disclosed |
| US-20030175680-A1 | Methods of treating and preventing bone loss | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-09-18 | — | — | US | disclosed |
| US-6001866-A | ADMINISTERING A COMPOUND WHICH IS AN INHIBITOR OF THE ENZYME 15-LIPOXYGENASE (15-LO). | WARNER-LAMBERT COMPANY (US) | 1999-12-14 | — | — | US | disclosed |
| US-5972980-A | ADMINISTERING AN LIPOXYGENASE INHIBITOR | WARNER-LAMBERT COMPANY (US) | 1999-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116415-A1 | Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators | NR5A1, ESRRA, SHBG | MEN1 2881/4885KMT2A 2260/4885ALOX15 2436/4885 |
| US-20060079488-A1 | Methods of treating and preventing bone loss | ALOX5, SOST, ALOX15B | MEN1 2480/4885KMT2A 3709/4885ALOX15 4/4885 |
| US-20090060905-A1 | Use of 15-Lipoxygenase Inhibitors for Treating Obesity | ALOX15, ALOX15B, ALOX12 | MEN1 4577/4885KMT2A 1931/4885ALOX15 1/4885 |
| US-20060116513-A1 | Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators | NR5A1, ESRRA, SHBG | MEN1 2881/4885KMT2A 2260/4885ALOX15 2436/4885 |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | ALOX15, ALOX15B, ALOX5 | MEN1 3283/4885KMT2A 3989/4885ALOX15 1/4885 |
| US-20030175680-A1 | Methods of treating and preventing bone loss | ALOX5, SOST, ALOX15B | MEN1 2480/4885KMT2A 3709/4885ALOX15 4/4885 |
| US-20210361693-A1 | PROCESS TO INHIBIT OR ELIMINATE EOSINOPHILIC DISEASES OF THE AIRWAY AND RELATED CONDITIONS | ALOX15, ALOX15B, ALOX5 | MEN1 4599/4885KMT2A 2994/4885ALOX15 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.